Keystone Investors’s Pfizer PFE Stock Holding History

Keystone Investors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-37,600	Closed	-$1.38M	–	47
2023 Q2	$1.38M	Buy	+37,600	New	+$1.46M	0.24%	29

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Keystone Investors's PFE Position: Q3 2023 in Review

Keystone Investors sold out of Pfizer (PFE) in Q3 2023, closing a stake of 37,600 shares — an estimated $1.38M sold.

Keystone Investors first reported a position in PFE in Q2 2023 and held it in 1 quarter. The position peaked at $1.38M in Q2 2023. 2,926 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Keystone Investors reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Keystone Investors sold 37,600 Pfizer shares in Q3 2023, an estimated $1.38M.
Keystone Investors first reported a position in Pfizer in Q2 2023 and held it in 1 quarter.
Keystone Investors's Pfizer position peaked at $1.38M in Q2 2023.
2,926 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Keystone Investors's 13F filing for Q3 2023, filed 13 Nov 2023.